Early access
Sign in
Taking people in United StatesEarly phase 1

Repeated CBD Administration and Cannabis Outcomes

Key facts

Who runs it
Hannah Harris
Where
Lexington, United StatesSee the site
Trial code
Status
Recruiting
Phase
Early phase 1
People taking part
23 people, planned
Started
5 Aug 2026
Expected to end
1 Dec 2029
Type of study
Interventional, 6 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Cannabidiol, Medium Dose
  • Cannabidiol, Higher Dose
  • Active Inhaled Cannabis
  • Placebo Cannabidiol
  • Placebo Inhaled Cannabis
Record updated
12 August 2026

Who can take part

Age
18 years to 55 years
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 20 criteriaShow less

Who can take part

  • English-speaking, literate adults,
  • Male or female,
  • Between the ages of 18-55,
  • Body Mass Index from 18.5-32.0 kg/m2,
  • Not currently seeking treatment for cannabis or drug use,
  • Able to provide written informed consent and perform all study procedures,
  • If female, a negative pregnancy test and use of an effective form of contraception during study participation (e.g., oral contraceptive, abstinence, barrier method),
  • Negative urine drug test for drugs of abuse (other than cannabis) prior to every Laboratory Session, and
  • Otherwise healthy as determined by the investigator based on medical history, physical examination, vital signs, and laboratory chemistries

Who cannot take part

  • Physiologic drug dependence on opioids, benzodiazepines, barbiturates, and/or alcohol that would require medical management,
  • Currently using daily prescription medications to manage medical conditions or any drug that could interfere with the study, including potent CYP2C9, CYP3A4, or CYP2C19 inducers,
  • Clinically significant acute medical problem (e.g., infection) or chronic medical problem requiring daily medication or ongoing medical care (e.g., hypertension, cardiovascular disease, diabetes, respiratory disorders [e.g., asthma, COPD]),
  • Current or past history of major psychiatric disorder that would limit ability to participate in the study,
  • History of seizure disorder,
  • Clinically significant history of head injuries requiring medical management or long lasting sequalae, and
  • Clinically significant abnormal laboratory findings,
  • Use of cannabis exclusively for medical reasons (no recreational use reported),
  • Current, unrelenting chronic pain that prevents participation (i.e., unable to sit in chair for 8 hours),
  • Clinically significant abnormal ECG (as determined by study physician/cardiologist),
  • Self-report of past 30-day use of synthetic cannabis (i.e., K2, Spice)

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 55 years old?

Where in United States

  • University of KentuckyLexington, United StatesContact: Paul A Nuzzo, M.A.Taking people

About the trial

What the trial wants to find out

This outpatient study examines how cannabidiol (CBD) affects the behavioral and pain-relieving effects of cannabis.

The 6 groups in the trial

  • Placebo CBD/Placebo Inhaled CannabisPlacebo, for comparison

    Participants will receive non-therapeutic, experimental doses of placebo/inactive cannabidiol in combination with non-therapeutic, placebo/inactive vaporized marijuana. Inactive cannabidiol and inactive marijuana will be administered once per session. It is possible to receive both inactive drugs on the same day. Inactive/Placebo Cannabidiol: Placebo/inactive cannabidiol will be administered orally. Inactive/Placebo: Experimental, non-therapeutic administration of an inactive/placebo marijuana dose will be administered through a vaporizer.

    Treatment: Placebo Cannabidiol and Placebo Inhaled Cannabis

  • Placebo CBD/Active Inhaled CannabisTreatment being tested

    Participants will receive a non-therapeutic, experimental dose of inactive/placebo cannabidiol in combination with non-therapeutic, active vaporized marijuana. It is possible to receive inactive cannabidiol and active marijuana on the same day. Inactive/Placebo Cannabidiol: Active cannabidiol will be administered orally. Active Marijuana: Experimental, non-therapeutic administration of an active marijuana dose will be administered through a vaporizer.

    Treatment: Active Inhaled Cannabis and Placebo Cannabidiol

  • CBD (Medium Dose)/Placebo Inhaled CannabisTreatment being tested

    Participants will receive a non-therapeutic, experimental dose of active cannabidiol in combination with non-therapeutic, inactive vaporized marijuana. It is possible to receive active cannabidiol, and inactive marijuana on the same day. Active Cannabidiol: Active cannabidiol will be administered orally. Inactive/Placebo Marijuana: Experimental, non-therapeutic administration of an inactive/placebo marijuana dose will be administered through a vaporizer.

    Treatment: Cannabidiol, Medium Dose and Placebo Inhaled Cannabis

  • CBD (Medium Dose)/Active Inhaled CannabisTreatment being tested

    Participants will receive non-therapeutic, experimental doses of active cannabidiol in combination with non-therapeutic, experimental doses of active vaporized marijuana. Cannabidiol and marijuana doses will be administered once during each session. It is possible to receive both active drugs on the same day. Vaporized Marijuana: Active Marijuana administered through a vaporizer Cannabidiol: Active cannabidiol will be administered orally

    Treatment: Cannabidiol, Medium Dose and Active Inhaled Cannabis

  • CBD (Higher Dose)/Placebo Inhaled CannabisTreatment being tested

    Participants will receive a non-therapeutic, experimental dose of active cannabidiol in combination with non-therapeutic, inactive vaporized marijuana. It is possible to receive active cannabidiol, and inactive marijuana on the same day. Active Cannabidiol: Active cannabidiol will be administered orally. Inactive/Placebo Marijuana: Experimental, non-therapeutic administration of an inactive/placebo marijuana dose will be administered through a vaporizer.

    Treatment: Cannabidiol, Higher Dose and Placebo Inhaled Cannabis

  • CBD (Higher Dose)/Active Inhaled CannabisTreatment being tested

    Participants will receive non-therapeutic, experimental doses of active cannabidiol in combination with a non-therapeutic, experimental dose of active vaporized marijuana. Active cannabidiol and marijuana doses will be administered once during each session. It is possible to receive both active drugs on the same day. Active Cannabidiol: Active cannabidiol will be administered orally. Active Marijuana: Active Marijuana will be administered through a vaporizer.

    Treatment: Cannabidiol, Higher Dose and Active Inhaled Cannabis

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
The Effects of Repeated CBD Administration on Cannabis Abuse Liability and Analgesia: A Human Laboratory Study
Fit questions
Built from NCT07434895, who can take part
Record updated
12 August 2026
Repeated CBD Administration and Cannabis Outcomes (NCT07434895) – Frontlight Research